Statin-induced myopathy risk was also predicted to be increased in more than half of the cohort due to variants in CYP2C9, SLCO1B1, and ABCG2. Moreover, we identified a commonly enriched potentially actionable variant, rs4149015, that is, related to pravastatin clearance. Here, CYP2C9 is linked to myopathy.